MovDisordV3, Main, Exploration, bibRecord, 006630

Antiparkinsonian activity of single oral dose of PHNO

Identifieur interne : 006630 ( Main/Exploration ); précédent : 006629; suivant : 006631

Antiparkinsonian activity of single oral dose of PHNO

Auteurs : F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; Marsden ; S. M. Stahl

Source :

Movement Disorders [ 0885-3185 ] ; 1987.

RBID : ISTEX:B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, Dose unique, Homme, Naphto oxazine(hydroxy-9 propyl-4), Parkinson maladie, Récepteur dopaminergique D2, Stimulant dopaminergique, Système nerveux pathologie, Toxicité, Traitement, Voie orale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Administration, Oral, Adult, Aged, Antiparkinson agent, Carbidopa (administration & dosage), Carbidopa (therapeutic use), Chemotherapy, Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine Agents (therapeutic use), Dopamine agonist, Dopaminergic receptor D2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Female, Human, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Oral administration, Oxazines (administration & dosage), Oxazines (adverse effects), Oxazines (therapeutic use), PHNO, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinson Disease, Secondary (pathology), Parkinson disease, Parkinson's disease, Reaction Time, Single dose, Toxicity, Treatment.
MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agents, Levodopa, Oxazines.
- chemical , adverse effects : Dopamine Agents, Oxazines.
- chemical , therapeutic use : Carbidopa, Dopamine Agents, Levodopa, Oxazines.
- chemically induced : Parkinson Disease, Secondary.
- drug therapy : Parkinson Disease, Secondary.
- pathology : Parkinson Disease, Secondary.
- Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Female, Humans, Male, Middle Aged, Reaction Time.

Abstract

PHNO, a new D‐2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose‐ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.

Url:

https://api.istex.fr/document/B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD/fulltext/pdf

DOI: 10.1002/mds.870020106

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of single oral dose of PHNO</title>
<author><name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name>
</author>
<author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name>
</author>
<author><name sortKey="Critchley, P" sort="Critchley, P" uniqKey="Critchley P" first="P." last="Critchley">P. Critchley</name>
</author>
<author><name sortKey="Rohan, A" sort="Rohan, A" uniqKey="Rohan A" first="A." last="Rohan">A. Rohan</name>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
</author>
<author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD</idno>
<date when="1987" year="1987">1987</date>
<idno type="doi">10.1002/mds.870020106</idno>
<idno type="url">https://api.istex.fr/document/B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003991</idno>
<idno type="wicri:Area/Istex/Curation">003991</idno>
<idno type="wicri:Area/Istex/Checkpoint">004603</idno>
<idno type="wicri:doubleKey">0885-3185:1987:Grandas F:antiparkinsonian:activity:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:2904120</idno>
<idno type="wicri:Area/PubMed/Corpus">005092</idno>
<idno type="wicri:Area/PubMed/Curation">005092</idno>
<idno type="wicri:Area/PubMed/Checkpoint">005088</idno>
<idno type="wicri:Area/Ncbi/Merge">004563</idno>
<idno type="wicri:Area/Ncbi/Curation">004563</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004563</idno>
<idno type="wicri:doubleKey">0885-3185:1987:Grandas F:antiparkinsonian:activity:of</idno>
<idno type="wicri:Area/Main/Merge">009A15</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:88-0130225</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003A93</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002D32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003A96</idno>
<idno type="wicri:doubleKey">0885-3185:1987:Grandas F:antiparkinsonian:activity:of</idno>
<idno type="wicri:Area/Main/Merge">009A55</idno>
<idno type="wicri:Area/Main/Curation">006630</idno>
<idno type="wicri:Area/Main/Exploration">006630</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian activity of single oral dose of PHNO</title>
<author><name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Critchley, P" sort="Critchley, P" uniqKey="Critchley P" first="P." last="Critchley">P. Critchley</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rohan, A" sort="Rohan, A" uniqKey="Rohan A" first="A." last="Rohan">A. Rohan</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name>
<affiliation><wicri:noCountry code="subField">London UK</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1987">1987</date>
<biblScope unit="vol">2</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="47">47</biblScope>
<biblScope unit="page" to="51">51</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD</idno>
<idno type="DOI">10.1002/mds.870020106</idno>
<idno type="ArticleID">MDS870020106</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiparkinson agent</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Dopaminergic receptor D2</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Oral administration</term>
<term>Oxazines (administration & dosage)</term>
<term>Oxazines (adverse effects)</term>
<term>Oxazines (therapeutic use)</term>
<term>PHNO</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (drug therapy)</term>
<term>Parkinson Disease, Secondary (pathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Reaction Time</term>
<term>Single dose</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Oxazines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term>
<term>Oxazines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Oxazines</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reaction Time</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Dose unique</term>
<term>Homme</term>
<term>Naphto oxazine(hydroxy-9 propyl-4)</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique D2</term>
<term>Stimulant dopaminergique</term>
<term>Système nerveux pathologie</term>
<term>Toxicité</term>
<term>Traitement</term>
<term>Voie orale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">PHNO, a new D‐2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose‐ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Critchley, P" sort="Critchley, P" uniqKey="Critchley P" first="P." last="Critchley">P. Critchley</name>
<name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name>
<name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
<name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name>
<name sortKey="Rohan, A" sort="Rohan, A" uniqKey="Rohan A" first="A." last="Rohan">A. Rohan</name>
<name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006630 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006630 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B9AEA15AD5CA96D1A36FD9BFA4604F1E037849DD
   |texte=   Antiparkinsonian activity of single oral dose of PHNO
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Antiparkinsonian activity of single oral dose of PHNO

Antiparkinsonian activity of single oral dose of PHNO

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.